Emergent Biosolutions (EBS) Set to Release Quarterly Earnings on Monday

Key Points

• Emergent BioSolutions is expected to report Q3 2026 results after Monday’s market close. Analysts forecast a loss of $0.37 per share on revenue of $123.22 million; the earnings call is scheduled for 5:00 p.m. ET.
• The company’s previous quarter exceeded expectations, with $0.60 EPS versus a projected $0.08 loss and revenue of $234.30 million versus estimates of $177.50 million. Analysts expect full-year EPS of $0.13 and next-year EPS of $0.74.
• EBS shares opened at $6.24, near their 50-day average of $6.29 and below the 200-day average of $7.34. Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $10.00.

Emergent Biosolutions (NYSE:EBS - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Emergent Biosolutions to post earnings of ($0.37) per share and revenue of $123.22 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, analysts expect Emergent Biosolutions to post $0.13 EPS for the current fiscal year and $0.74 EPS for the next fiscal year.

Emergent Biosolutions Stock Up 0.2%

Shares of NYSE:EBS opened at $6.24 on Monday. The firm's 50 day moving average price is $6.29 and its 200 day moving average price is $7.34. The stock has a market cap of $320.08 million, a price-to-earnings ratio of -1.76 and a beta of 2.28. Emergent Biosolutions has a fifty-two week low of $4.36 and a fifty-two week high of $14.06. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70.

Insider Activity at Emergent Biosolutions

In other news, Director Donald Degolyer sold 17,800 shares of the stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the transaction, the director owned 111,921 shares in the company, valued at approximately $793,519.89. This represents a 13.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on EBS shares. Weiss Ratings upgraded shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st. Zacks Research upgraded shares of Emergent Biosolutions to a "hold" rating in a report on Tuesday, August 11th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. Finally, JPMorgan Chase & Co. started coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an "underweight" rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Emergent Biosolutions presently has an average rating of "Hold" and an average price target of $10.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.